Sequenom, Inc. SQNM, a life
sciences company providing innovative diagnostic testing and genetic analysis
solutions, today announced its wholly-owned subsidiary, Sequenom Center for
Molecular Medicine (Sequenom CMM), presented results from a study of its
RetnaGene AMD laboratory-developed test to predict risk of disease progression
during the 2012 Joint Meeting of the American Academy of Ophthalmology and the
Asia-Pacific Academy of Ophthalmology in Chicago.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in